Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. J of Skin [Internet]. 2022 Mar. 4 [cited 2025 May 18];6(2):s1. Available from: https://skin.dermsquared.com/skin/article/view/1516